Charles M. Baum, M.D., PH.D. Joins Array BioPharma Board Of Directors
PR Newswire - Mon Apr 28, 3:00PM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014.
Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023
PR Newswire - Thu Apr 03, 10:00AM CDT
Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel's sapacitabine, Mirati Therapeutics' mocetinostat, Celgene's oral azacitidine, Onconova's oral rigosertib and Acceleron/Celgene's sotatercept, as well as a label extension for GlaxoSmithKline's Revolade/Promacta.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 24, 2:40PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
William R. Ringo Joins Mirati Board of Directors
PR Newswire - Thu Mar 20, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of directors.
Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:01PM CDT
Mirati Therapeutics, Inc. ("Mirati"
2 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 25, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Mirati Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 05, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13 at 1:00 PM Eastern Time in New York.
Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
PR Newswire - Mon Dec 09, 9:10AM CST
Mirati Therapeutics, Inc. ("Mirati"
Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Dec 02, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 10:30 AM Eastern Time in New York.
Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Fri Nov 22, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Marketwire - Wed Sep 04, 5:31AM CDT
Mirati Therapeutics (NASDAQ: MRTX) today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its board of directors and as the chairman of the audit committee.
Mirati Therapeutics Reports Second Quarter 2013 Financial Results
Marketwire - Mon Aug 12, 5:31AM CDT
Mirati Therapeutics, Inc. ("Mirati"
Mirati Therapeutics to Voluntarily Delist from TSX
Marketwire - Fri Jul 19, 3:22PM CDT
Mirati Therapeutics Inc. (TSX: MYG)(NASDAQ: MRTX) ("Mirati Therapeutics"
LifeSci Advisors Initiates Coverage of Mirati Therapeutics
Marketwire - Thu Jul 18, 8:02AM CDT
LifeSci Advisors, LLC (NASDAQ: MRTX) (TSX: MYG)
Mirati Therapeutics to Commence Trading on the NASDAQ
Marketwire - Mon Jul 15, 7:15AM CDT
Mirati Therapeutics Inc. ("Mirati Therapeutics" or the "Company"